Sangui Biotech International (SGBI) 10-Q/A2021 Q3 Quarterly report (amended)

Filed: 7 May 21, 5:25pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: abandon, advanced, advice, allocate, allocated, analogously, announced, annually, ArbnErfG, Asian, asset, ASU, attention, automobile, bearing, began, beginning, Benelux, brand, clear, combined, complying, confident, contact, contractor, cooperation, core, create, criteria, decided, declared, demand, denominated, depict, desired, diabetic, Director, discounted, drastically, earliest, Eastern, elasticity, emerged, emerging, Employee, enterprise, entity, entry, essentially, exceed, expedite, expired, exposed, extent, facilitate, factor, FASB, Fast, fill, foot, foreseeable, founded, Georgsmarienhuette, guidance, Hamburg, Healthcare, Heath, higher, highest, home, II, independent, individual, Infirst, KG, Law, lease, leased, leasing, lessee, lessened, long, mandating, member, merged, merger, Mexico, modified, moisturizing, monthly, November, October, option, overcome, pandemic, parent, partner, partnership, party, Patentverwertungsgesellschaft, payment, people, Pharma, point, policy, Prior, priority, private, professional, project, promised, promising, public, purpose, pursuit, quarantining, recent, recently, registered, remuneration, rent, response, responsible, resumed, retrospective, revaluation, revised, SanderStrohmann, satisfied, segment, September, set, SGBI, South, spread, stage, stake, standard, stay, Stockholder, strength, suspended, Symbol, table, temporarily, top, Topic, traced, Track, transaction, transfer, transferred, transition, transparency, travel, treasury, und, unmet, unsecured, volatile, world

Removed: abdomen, add, adjusted, aimed, amending, amounted, animal, annum, applicable, applying, assured, August, awarded, begun, binding, call, carried, carrier, CFO, clearance, Cluster, collection, commenced, complemented, complementing, contractual, cordially, corporate, cumulated, customer, deemed, demonstrated, depreciated, determined, distribute, elapsed, enter, EP, equipment, error, EUR, exceeded, Excellence, experience, failing, fixed, Fleing, FOB, formulation, fourth, FY, Gesellschaft, Giessen, governed, government, haemoglobin, half, hyperpolymer, improve, increasing, institution, integrity, intent, interrupted, intestinal, investigate, investigating, investment, Joachim, legally, level, licensor, liquid, mortality, ninety, notice, notified, objection, obtained, Original, origination, oxygenation, partly, patient, percent, percentage, permanently, Pertain, phase, post, posted, preparing, property, refund, resistant, respiratory, restoration, SanguiBioTech, secured, septic, shareholder, shipment, shipped, shock, significantly, site, slightly, stringent, substitute, successfully, survival, syndrome, targeting, Technologietransfer, therapeutic, trade, TransMIT, treating, ultimately, university, unrealized, uppermost, USD, vivo, web, Witten, zone

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

SGBI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.01

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Sangui Biotech International, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas Striepe, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Dated: May 07, 2021/s/ Thomas Striepe

By: Thomas Striepe

Chief Executive Officer and

Chief Financial Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.